Johns Hopkins researchers report in Annals of Internal Medicine that the pill brought in new patients instead of pulling users away from injectable semaglutide.
Recap by typeshit. Full story at Newswise.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Novo pays $300 million upfront for HRS-1596, and the OCTANE trial reports 4.1% average weight loss after patients switched from injections to oral semaglutide.
Medical Xpress reports a small pilot study where people coming off GLP-1 treatment got structured support, with early signs it may help them keep weight off.
Loading…